Company
Every investor coverage indicates participated in a round Roche raised.
Companies Roche acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Roche. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sanofi is buying Vicebio for up to US$1.6 billion in the biggest-ever exit of Australian university IP, with UQ keeping equity; the article also recalls the Inflazome and Spinifex sales and Vicebio's Medicxi seed.
Profile of Australian biotech Recce Pharmaceuticals, whose synthetic antibiotic candidates target drug-resistant infections, covering its leadership team, FDA designation, clinical trial progress and a government underwriting of its R&D rebate.
Sydney diagnostics developer SpeeDx banked $26 million for American expansion, with $5 million from Andrew Forrest's new fund Tenmile and follow-on support from Platinum and Northpond.
Also SmartCompany
Sydney clinical trials platform HealthMatch raised a $10 million Series C led by Folklore Ventures with Square Peg participating, after laying off half its staff in June; funds will support rehiring and US expansion.
Also SmartCompany·Techboard
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
Australian pharmaceutical developer Hatchtech appoints Tim Waugh, a former Roche divisional vice president, as chief executive officer to lead development and commercialisation of its head lice treatment DeOvo and establish a United States presence.
Biotech Proacta's release: its Phase I cancer-drug trial is underway, and Alta Partners' new funding tops the Series A up to $12M alongside lead backer GBS Ventures; Alta's David Mack joins the board.
Folklore Ventures founder story recalling its seed backing of Manuri Gunawardena's clinical trial matching startup HealthMatch, plus follow-ons in its Series A and December 2020 Series B alongside Square Peg.